A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1h-benzimidazole-4- carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemias

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 1, 2009, Pages 10-18

  Oh, Kwang Seok ^a   Lee, Sunkyung ^a   Yi, Kyu Yang ^a   Seo, Ho Won ^a   Koo, Hyun Na ^a   Lee, Byung Ho ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 [CARBOXY (4 METHOXYPHENYL)METHYLSULFANYL] 1H BENZIMIDAZOLE 4 CARBOXYLIC ACID AMIDE; 2 [METHOXYCARBONYL (4 METHOXYPHENYL)METHYLSULFANYL] 1H BENZIMIDAZOLE 4 CARBOXYLIC ACID AMIDE; HYDROGEN PEROXIDE; KR 33889; KR 34285; KR 34314; LACTATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TM 0261; UNCLASSIFIED DRUG; 2 (METHOXYCARBONYL(4 METHOXYPHENYL)METHYLSULFANYL) 1H BENZIMIDAZOLE 4 CARBOXYLIC ACID AMIDE; 2-(METHOXYCARBONYL(4-METHOXYPHENYL)METHYLSULFANYL)-1H-BENZIMIDAZOLE-4-CARBOXYLIC ACID AMIDE; ADPRT PROTEIN, RAT; BENZIMIDAZOLE DERIVATIVE; CARDIOTONIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHENYLACETIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME RELEASE; H9C2 CELL; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; TIME TO MAXIMUM PLASMA CONCENTRATION; WESTERN BLOTTING; ANIMAL; CELL LINE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; HEART MITOCHONDRION; HEART MUSCLE REPERFUSION; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BENZIMIDAZOLES; CARDIOTONIC AGENTS; CELL DEATH; CELL LINE; ENZYME ACTIVATION; HYDROGEN PEROXIDE; MALE; MITOCHONDRIA, HEART; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; PHENYLACETATES; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 59149087137     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.143719     Document Type: Article

References (28)

1. Bowes J, McDonald MC, Piper J, and Thiemermann C (1999) Inhibitors of poly (ADP-ribose) synthetase protect rat cardiomyocytes against oxidant stress. Cardiovasc Res 41:126-134.
2. Bowes J, Piper J, and Thiemermann C (1998) Inhibitors of the activity of poly (ADP-ribose) synthetase reduce the cell death caused by hydrogen peroxide in human cardiac myoblasts. Br J Pharmacol 124:1760-1766.
3. Curtin NJ (2005) PARP inhibitors for cancer therapy. Expert Rev Mol Med 7:1-20.
4. Erdélyi K, Bakondi E, Gergely P, Szabó C, and Virág L (2005) Pathophysiologic role of oxidative stress-induced poly (ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation. Cell Mol Life Sci 62:751-759.
5. Ferdinandy P, Schulz R, and Baxter GF (2007) Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postcon-ditioning. Pharmacol Rev 59:418-458.
6. Filipovic DM, Meng X, and Reeves WB (1999) Inhibition of PARP prevents oxidant-induced necrosis but not apoptosis in LLC-PK1 cells. Am J Physiol 277:F428-F436.
7. Gilad E, Zingarelli B, Salzman AL, and Szabo C (1997) Protection by inhibition of poly (ADP-ribose) synthetase against oxidant injury in cardiac myoblasts in vitro. J Mol Cell Cardiol 29:2585-2597.
8. Ikai K and Ueda K (1983) Immunohistochemical demonstration of poly(adenosine diphosphate-ribose) synthetase in bovine tissues. J Histochem Cytochem 31:1261-1264.
9. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
10. Ishida J, Yamamoto H, Kido Y, Kamijo K, Murano K, Miyake H, Ohkubo M, Kinoshita T, Warizaya M, Iwashita A, et al. (2006) Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling. Bioorg Med Chem 14:1378-1390.
11. Jagtap P and Szabó C (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4:421-440.
12. + exchanger. Eur J Pharmacol 535:220-227.
13. +-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP. Cell 119:803-814.
14. Kraus WL and Lis JT (2003) PARP goes transcription. Cell 113:677-683.
15. Lee BH, Seo HW, and Yoo SE (2004) Cardioprotective effects of (2S,3R,4S)-N-benzyl-N"-cyano-N-(3,4-dihydro-2-dimethoxymethyl-3- hydroxy-2-methyl-6-nitro-2H-benzopyran-4-yl)-guanidine (KR-31372) in rats and dogs. Pharmacology 70:74-82.
16. Lee BH, Yi KY, Lee S, Lee S, and Yoo SE (2005a) Effects ofKR-32570, a new sodium hydrogen exchanger inhibitor, on myocardial infarction and arrhythmias induced by ischemia and reperfusion. Eur J Pharmacol 523:101-108.
17. Lee S, Koo HN, and Lee BH (2005b) Development of a miniaturized assay for the high-throughput screening program for poly(ADP-ribose) polymerase-1. Methods Find Exp Clin Pharmacol 27:617-622.
18. Meyer-Ficca ML, Meyer RG, Jacobson EL, and Jacobson MK (2005) Poly(ADP-ribose) polymerases: managing genome stability. Int J Biochem Cell Biol 37:920-926.
19. Nakajima H, Kakui N, Ohkuma K, Ishikawa M, and Hasegawa T (2005) A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8- tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuro-protective effects, and therapeutic time window in cerebral ischemia in rats. J Pharmacol Exp Ther 312:472-481.
20. Pieper AA, Walles T, Wei G, Clements EE, Verma A, Snyder SH, and Zweier JL (2000) Myocardial postischemic injury is reduced by poly (ADP-ribose) polymer-ase-1 gene disruption. Mol Med 6:271-282.
21. Szabó G, Bährle S, Stumpf N, Sonnenberg K, Szabó EE, Pacher P, Csont T, Schulz R, Dengler TJ, Liaudet L, et al. (2002) Poly (ADP-ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res 90:100-106.
22. Thies RL and Autor AP (1991) Reactive oxygen injury to cultured pulmonary artery
23. endothelial cells: mediation by poly (ADP-ribose) polymerase activation causing NAD depletion and altered energy balance. Arch Biochem Biophys 286:353-363.
24. Tulin A, Chinenov Y, and Spradling A (2003) Regulation of chromatin structure and gene activity by poly(ADP-ribose) polymerases. Curr Top Dev Biol 56:55-83.
25. Wayman N, McDonald MC, Thompson AS, Threadgill MD, and Thiemermann C (2001) 5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5́-diphosphate ribose) polymerase, reduces myocardial infarct size. Eur J Pharmacol 430:93-100.
26. Yang YG, Cortes U, Patnaik S, Jasin M, and Wang ZQ (2004) Ablation of PARP does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene 23:3872-3882.
27. Yang Z, Zingarelli B, and Szabó C (2000) Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. Shock 13:60-66.
28. Zingarelli B, Cuzzocrea S, Zsengellér Z, Salzman AL, and Szabó C (1997) Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase. Cardiovasc Res 36:205-215.